Yahoo Finance Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus
For Immediate Release
Chicago, IL – April 4, 2023 – Stocks in this week’s article are Bellerophon Therapeutics Inc. BLPH, Crawford & Co. (CRD.B), Riley Exploration Permian Inc. REPX, Harrow Health Inc. HROW and Lantheus Holdings Inc. LNTH.
5 Stocks with Recent Price Strength Amid March Rally
Wall Street has concluded an impressive March as well as an eventful and solid first quarter. Timely intervention by the U.S. government and the Fed to resolve the banking sector crisis strengthened market participants’ confidence. Moreover, a moderate reading of the Fed’s most favorite inflation gauge — the core PCE (personal consumption expenditure) price index — also lifted investor sentiment.
The higher interest rate regime took its toll on the banking sector in the United States and Eurozone. This along with the recently released several weak economic data compelled the central bank to stick to a 25 basis-point rate hike in the March FOMC meeting and to reaffirm the terminal rate at 5.125%. Powell also said that the rate hike cycle is approaching its end.
Consequently, Wall Street closed a strong March as the Dow, the S&P 500 and the Nasdaq Composite advanced 1.9%, 3.5% and 6.7%, respectively. U.S. stock markets finished first-quarter 2023 on a positive note too. The Dow, the S&P 500 and the Nasdaq Composite surged 0.4%, 7% and 16.8%, respectively. The Nasdaq Composite posted its biggest quarterly gain since the quarter ended June 2020.
As a result, several stocks have shown price strength. We have selected five of them that are likely to gain in the near term backed by a favorable Zacks Rank. These companies are — Bellerophon Therapeutics Inc., Crawford & Co., Riley Exploration Permian Inc., Harrow Health Inc. and Lantheus Holdings Inc.
Here’s How We Arrived at the Picks
We have primarily targeted stocks that have freshly been on a bull run. Stocks seeing price strength recently have a high chance of carrying the momentum forward.
If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.
Here’s how you should create the screen to shortlist the current as well as the potential winners.
Let’s discuss five out of these 10 stocks:
Bellerophon Therapeutics is a biotherapeutics company. BLPH is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. BLPH’s product pipeline consists of INOpulse and BCM which are in different clinical stages.
The stock price of Bellerophon Therapeutics has soared 336.3% in the past four weeks. It has expected earnings growth of 18.8% for the current year. The Zacks Consensus Estimate for the current year has improved 4.5% over the last 30 days.
Crawford is the world's largest independent provider of diversified services to insurance companies, self-insured corporations, and governmental entities. CRD.B operates through four segments: North America Loss Adjusting, International Operations, Broadspire, and Platform Solutions.
CRD.B provides claims management and outsourcing solutions for carriers, brokers, and corporations in the United States, the United Kingdom, Europe, Canada, Australia, Asia, and Latin America.
The stock price of Crawford has jumped 40.2% in the past four weeks. It has an expected earnings growth rate of 22.9% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.01% over the last seven days.
Riley Exploration is an independent oil and natural gas company. REPX is involved in the acquisition, exploration, development and production of oil, natural gas, and natural gas liquids principally in the Permian Basin.
The stock price of REPX has climbed 15% in the past four weeks. It has an expected earnings growth rate 50.5% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 42.3% over the last 30 days.
Harrow Health is an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. HROW offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. HROW also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA and MAXITROL eye drops.
The stock price of Harrow Health has surged 13.4% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for next-year earnings has improved 40.9% over the last seven days.
Lantheus Holdings is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for the diagnosis of cardiovascular and other diseases. LNTH serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers.
The stock price of Lantheus Holdings has advanced 13.2% in the past four weeks. It has an expected earnings growth rate of 13.5% for the current year. The Zacks Consensus Estimate for current-year earnings improved 12.7% over the last 60 days.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2073571/5-stocks-with-recent-price-strength-amid-march-rally
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Crawford & Company (CRD.B) : Free Stock Analysis Report
Bellerophon Therapeutics, Inc. (BLPH) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
Harrow Health, Inc. (HROW) : Free Stock Analysis Report
Riley Exploration Permian, Inc. (REPX) : Free Stock Analysis Report
